Effects of long-term administration of high-dose recombinant human antithrombin in immunosuppressed primate recipients of porcine xenografts

Transplantation

Volumn 80, Issue 10, 2005, Pages 1501-1510

  Cozzi, Emanuele ^a,b,c   Simioni, Paolo ^a,c   Boldrin, Massimo ^b   Seveso, Michela ^b   Calabrese, Fiorella ^c   Baldan, Nicola ^a,b,c   Busetto, Roberta ^c   Tormene, Daniela ^a,c   Gavasso, Sabrina ^a,c   Castagnaro, Massimo ^d   Echelard, Yann ^e   Rice, Tim ^e   Plebani, Mario ^a   Carraro, Paolo ^a   Bosio, Erika ^b,c   Valente, Marialuisa ^c   Pagnan, Antonio ^a,c   Thiene, Gaetano ^c   Ancona, Ermanno ^a,b,c  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^b CORIT ^*  (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Veterinary Pathology and Hygiene Institute Padua   (Italy)

^e GTC Biotherapeutics Inc   (United States)

Author keywords

Coagulopathy; Humoral rejection; Pig; Primate; Recombinant antithrombin; Xenotransplantation

Indexed keywords

RECOMBINANT HUMAN ANTITHROMBIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING TENDENCY; BLOOD CLOTTING; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG MEGADOSE; FIBRIN FORMATION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; MALE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; SWINE; TREATMENT FAILURE; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTITHROMBINS; FIBRIN; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MACACA FASCICULARIS; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTEIN S; RECOMBINANT PROTEINS; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 29144483474     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000178377.55615.8B     Document Type: Article

References (29)

1. Ierino FL, Kozlowski T, Siegel JB, et al. Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts. Transplantation 1998; 66(11): 1439.
2. Robson SC, Cooper DK, d'Apice AJ. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 2000; 7(3): 166.
3. Buhler L, Yamada K, Kitamura H, et al. Pig kidney transplantation in baboons: anti-Gal(alpha)1-3Gal IgM alone is associated with acute humoral xenograft rejection and disseminated intravascular coagulation. Transplantation 2001; 72(11): 1743.
4. Gaca JG, Lesher A, Aksoy O, et al. Disseminated intravascular coagulation in association with pig-to-primate pulmonary xenotransplantation. Transplantation 2002; 73(11): 1717.
5. Cozzi E, Simioni P, Boldrin M, et al. Alterations in the coagulation profile in renal pig-to-monkey xenotransplantation. Am J Transplant 2004; 4(3): 335.
6. Cozzi E, Cadrobbi R, Baldan N, et al. Methotrexate tor immunosuppression in life-supporting pig-to-cynomolgus monkey renal xenotransplantation. Xenotransplantation 2003; 10(6): 587.
7. Zaidi A, Schmoeckel M, Bhatti F, et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 1998; 65(12): 1584.
8. Cozzi E, Bhatti F, Schmoeckel M, et al. Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts. Transplantation 2000; 70(1): 15.
9. Loss M, Vangerow B, Schmidtko J, et al. Acute vascular rejection is associated with systemic complement activation in a pig-to-primate kidney xenograft model. Xenotransplantation 2000; 7(3): 186.
10. Cozzi E, Vial C, Ostlie D, et al. Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts. Xenotransplantation 2003; 10(4): 300.
11. Ghanekar A, Lajoie G, Luo Y, et al. Improvement in rejection of human decay accelerating factor transgenic pig-to-primate renal xenografts with administration of rabbit antithymocyte serum. Transplantation 2002; 74(1): 28.
12. McGregor CG, Teotia SS, Schirmer JM, et al. Cardiac xenotransplantation: 4 1/2 month survival in the laboratory. Xenotransplantation 2003; 10(5): 480.
13. Cowan PJ, Aminian A, Barlow H, et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 2000; 69(12): 2504.
14. Schuurman HJ, Pino-Chavez G, Phillips MJ, et al. Incidence of hyperacute rejection in pig-to-primate transplantation using organs trom hDAF-transgenic donors. Transplantation 2002; 73(7): 1146.
15. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24(1): 19.
16. Minnema MC, Chang AC, Jansen PM, et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95(4): 1117.
17. Taylor FB, Jr., Chang AC, Peer GT, et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991; 78(2): 364.
18. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin Thromb Hemost 1998; 24(1): 27.
19. DePalo V, Kessler C, Opal SM. Success or failure in phase III sepsis trials: comparison between the Drotrecogin alpha (activated) and Antithrombin III clinical trials. Advances in Sepsis 2001; 1(4): 114.
20. Cowan PJ, Aminian A, Barlow H, et al. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2002; 2(6): 520.
21. Cozzi E, White DJ. The generation of transgenic pigs as potential organ donors for humans. Nat Med 1995; 1(9): 964.
22. Katopodis AG, Warner RG, Duthaler RO, et al. Removal of anti-Galalpha1,3Gal xenoantibodies with an injectable polymer. J Clin Invest 2002; 110(12): 1869.
23. Kessler CM, Tang Z, Jacobs HM, Szymanski LM. The suprapharmacologic closing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 1997; 89(12): 4393.
24. Simioni P, Tormene D, Manfrin D, et al. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 1998; 103(4): 1045.
25. Simioni P, Vianello F, Kalafatis M, et al. A dysfunctional factor X (factor X San Giovanni Rotondo) present at homozygous and double heterozygous level: identification of a novel microdeletion (delC556) and missense mutation (Lys(408)->Asn) in the factor X gene. A study of an Italian family. Thromb Res 2001; 101 (4): 219.
26. Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998; 24(1): 3.
27. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Jama 2001; 286(15): 1869.
28. Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med 2002; 30(5 Suppl): S325.
29. Wiedermann J, Romisch J. The anti-inflammatory actions of antithrombin - a review. Acta Med Austriaca 2002; 29(3): 89.